BBOT BridgeBio Oncology Therapeutics, Inc. - Common Stock
$9,40
Kurs · Aug 19, 2026
Fundamentaldaten per Aug 11, 2026
52W-Spanne
$7–$15
30% of range
Analystenbewertung
BUY
17 analysts
Kursziel
$25
+167% upside
P/E (TTM)
-2.2
ROE
-146.2%
Nettogewinnmarge
—
BBOT Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$9.40
Marktkapitalisierung
$752M
P/E (TTM)
-2.2
EPS (TTM)
$-4.30
Umsatz (TTM)
—
Dividendenrendite
—
ROE
-146.2%
Verschuldungsgrad
0.0
52W-Spanne
$7 – $15
BBOT Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Configure
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz & Nettoergebnis
—
EPS
$-4.30
2024-12-31
→
2025-12-31
Freier Cashflow
$-114M
2025-12-31
→
2025-12-31
Margen
—
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
Kennzahl
5-Jahres-Trend
BBOT
Peer-Median
P/E (TTM)
-2.2
70.4
P/B (K/B)
1.8
2.2
EV / EBITDA
-2.2
—
Price / FCF (Kurs / FCF)
-6.6
—
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
Kennzahl
5-Jahres-Trend
BBOT
Peer-Median
ROA
-43.8%
-35.6%
ROE
-146.2%
-37.4%
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
Kennzahl
5-Jahres-Trend
BBOT
Peer-Median
Debt / Equity (Fremdkapital / Eigenkapital)
0.0
—
Current Ratio (Liquiditätsgrad)
12.3
7.1
Quick Ratio
12.1
—
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Kennzahl
5-Jahres-Trend
BBOT
Peer-Median
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Kennzahl
5-Jahres-Trend
BBOT
Peer-Median
BBOT Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
KAUF
17 Analysten
- Starker Kauf 6 35,3%
- Kauf 10 58,8%
- Halten 1 5,9%
- Verkauf 0 0,0%
- Starker Verkauf 0 0,0%
12-Monats-Kursziel
10 Analysten · 2026-08-15
Median
$23.50
← Unter allen Zielen
$9.40
Tief
$18.00
Hoch
$39.00
Median-Ziel
$23.50
+150,0%
Mittelwert-Ziel
$25.10
+167,0%
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
-0.20%
| Zeitraum | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|
| 31. März 2026 | $-0.53 | $-0.54 | 0.01% |
| 31. Dezember 2025 | $-0.49 | $-0.53 | 0.04% |
| 30. September 2025 | $-1.03 | $-0.40 | -0.63% |
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| BBOT | $1.00B | -2.9 | — | — | -146.2% | — |
| MNPR | — | — | — | — | — | — |
| CTMX | $725M | — | -44.8% | -22.8% | -15.9% | — |
| RGNX | $733M | -3.8 | 104.5% | -113.8% | -122.5% | — |
| NGNE | $319M | -4.9 | — | — | -33.6% | — |
| STTK | $231M | -5.2 | -82.5% | -4880.9% | -70.0% | — |
| GYRE | $645M | 353.0 | 10.2% | 8.5% | 11.7% | — |
| NVCT | $194M | -5.7 | — | — | -149.9% | — |
| ALLO | $314M | -1.6 | -76.8% | — | -59.9% | — |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung 13
| Kennzahl | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| R&D Expense | $121M | $73M | · | |
| SG&A Expense | $25M | $8M | $41.7K | |
| Operating Expenses | $146M | $81M | · | |
| Operating Income | $-146M | $-81M | $-41.7K | |
| Interest Income | $11M | $6M | · | |
| Other Non-op | $-35.0K | $0 | · | |
| Income Tax | $0 | $0 | · | |
| Net Income | $-134M | $-74M | $-41.7K | |
| EPS (Basic) | $-4.30 | $-5756.41 | · | |
| EPS (Diluted) | $-4.30 | $-5756.41 | · | |
| Shares (Basic) | 31,144,775 | 12,903 | · | |
| Shares (Diluted) | 31,144,775 | 12,903 | · | |
| EBITDA | $-146M | $-584.4K | · |
Bilanz 21
| Kennzahl | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Cash & Equivalents | $374M | $31M | $0 | |
| Short-term Investments | $52M | $125M | · | |
| Prepaid Expense | $7M | $3M | · | |
| Current Assets | $432M | $159M | · | |
| PP&E (Net) | $956.0K | $490.0K | · | |
| Other Non-current Assets | $13M | $5M | · | |
| Total Assets | $448M | $164M | $332.9K | |
| Accounts Payable | $1M | $3M | · | |
| Accrued Liabilities | · | $119.7K | $15.0K | |
| Short-term Debt | $534.0K | $483.0K | $70.1K | |
| Current Liabilities | $35M | $20M | $396.5K | |
| Capital Leases | $2M | $0 | · | |
| Total Liabilities | $37M | $20M | $396.5K | |
| Total Debt | $534.0K | · | · | |
| Common Stock | $8.0K | $0 | · | |
| Paid-in Capital | $768M | $44M | $24.5K | |
| Retained Earnings | $-357M | $-223M | $-88.6K | |
| AOCI | $16.0K | $348.0K | · | |
| Stockholders' Equity | $411M | $-179M | $-116M | |
| Liabilities + Equity | $448M | $164M | $332.9K | |
| Shares Outstanding | 79,991,768 | 28,415 | · |
Cashflow 9
| Kennzahl | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Stock-based Comp | $6M | $4M | · | |
| Deferred Tax | $0 | $0 | · | |
| Operating Cash Flow | $-114M | $-55M | · | |
| CapEx | $606.0K | $49.0K | · | |
| Investing Cash Flow | $73M | $-121M | · | |
| Stock Issued | $112M | · | · | |
| Net Stock Activity | $112M | · | · | |
| Financing Cash Flow | $383M | $206M | · | |
| Free Cash Flow | $-114M | · | · |
Rentabilität 2
| Kennzahl | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| ROA | -43.8% | 7.8% | · | |
| ROE | -146.2% | -9.3% | · |
Liquidität & Solvenz 3
| Kennzahl | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Current Ratio | 12.3 | 10.4 | · | |
| Quick Ratio | 12.1 | 9.1 | · | |
| Debt / Equity | 0.0 | · | · |
Bewertung (TTM) 11
| Kennzahl | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Net Income TTM | $-134M | $-74M | · | |
| Market Cap | $1.00B | · | · | |
| Enterprise Value | $577M | · | · | |
| P/E | -2.9 | -0.0 | · | |
| P/B | 2.4 | · | · | |
| P / Tangible Book | 2.4 | · | · | |
| P / Cash Flow | -8.8 | · | · | |
| P / FCF | -8.7 | · | · | |
| EV / EBITDA | -4.0 | · | · | |
| EV / FCF | -5.0 | · | · | |
| Earnings Yield | -34.4% | -54823.0% | · |
Gewinn- und Verlustrechnung 13
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $49M | $40M | $38M | $35M | $27M | $21M | $20M | $18M | · | · | |
| SG&A Expense | $11M | $6M | $7M | $14M | $3M | $3M | $6M | $2M | $152.3K | $66.7K | |
| Operating Expenses | $60M | $46M | $43M | $49M | $30M | $23M | $22M | $20M | · | · | |
| Operating Income | $-60M | $-46M | $-93M | $-49M | $-30M | $-23M | $-61M | $-20M | $-152.3K | $-66.7K | |
| Interest Income | $4M | $4M | $4M | $3M | $2M | $2M | $255.2K | $2M | $2M | $1M | |
| Other Non-op | $-14.0K | $-94.0K | $-4M | $-30.0K | $-8.0K | $-2.0K | $-4M | $0 | $2M | $1M | |
| Income Tax | $0 | · | $0 | $0 | $0 | $0 | $0 | $0 | · | · | |
| Net Income | $-56M | $-42M | $-39M | $-45M | $-28M | $-22M | $-20M | $-17M | $-22M | $-15M | |
| EPS (Basic) | $-705.20 | $-526.11 | $2.19 | $-1.03 | $-566.46 | $-54.23 | $-833.69 | $-1562.18 | · | · | |
| EPS (Diluted) | $-705.20 | $-526.11 | $2.19 | $-1.03 | $-566.46 | $-54.23 | $-833.69 | $-1562.18 | · | · | |
| Shares (Basic) | 80,054,000 | 80,032 | 16,459,785 | 43,491,085 | 50,198,000 | 406,723 | 1,814 | 11,089 | · | · | |
| Shares (Diluted) | 80,054,000 | 80,032 | 16,459,785 | 43,491,085 | 50,198,000 | 406,723 | 1,814 | 11,089 | · | · | |
| EBITDA | $-60M | $-46M | · | $-49M | $-1M | $-2M | · | $-146.9K | $-152.3K | $-66.7K |
Bilanz 21
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $54M | $53M | $374M | $409M | $664.2K | $963.1K | $31M | $2M | $2M | $2M | |
| Short-term Investments | $172M | $200M | $52M | $60M | · | · | $125M | · | · | · | |
| Prepaid Expense | $16M | $14M | $7M | $7M | $62.5K | · | $3M | · | $11.3K | $16.3K | |
| Current Assets | $242M | $267M | $432M | $476M | $876.8K | $1M | $159M | $2M | $2M | $2M | |
| PP&E (Net) | $878.0K | $938.0K | $956.0K | $827.0K | · | · | $490.0K | · | · | · | |
| Other Non-current Assets | $13M | $11M | $13M | $5M | · | · | $5M | · | · | · | |
| Total Assets | $377M | $418M | $448M | $485M | $197M | $196M | $164M | $192M | $190M | $188M | |
| Accounts Payable | $7M | $12M | $1M | $4M | $3M | · | $3M | · | · | · | |
| Accrued Liabilities | · | · | · | · | · | $2M | · | $126.7K | $79.1K | $23.3K | |
| Short-term Debt | · | $716.0K | $534.0K | $691.0K | · | · | $483.0K | · | · | · | |
| Current Liabilities | $52M | $43M | $35M | $36M | $3M | $2M | $20M | $126.7K | $79.1K | $23.3K | |
| Capital Leases | $2M | $2M | $2M | $2M | · | · | $0 | · | · | · | |
| Total Liabilities | $54M | $45M | $37M | $38M | $8M | $7M | $20M | $6M | $6M | $6M | |
| Total Debt | · | $716.0K | · | $691.0K | · | · | · | · | · | · | |
| Common Stock | $8.0K | $8.0K | $8.0K | $8.0K | · | · | $0 | · | · | $51 | |
| Paid-in Capital | $779M | $772M | $768M | $764M | · | · | $44M | · | · | · | |
| Retained Earnings | $-455M | $-399M | $-357M | $-318M | $-7M | $-6M | $-223M | $-4M | $-3M | $-3M | |
| AOCI | $-959.0K | $-981.0K | $16.0K | $36.0K | · | · | $348.0K | · | · | · | |
| Stockholders' Equity | $323M | $372M | $411M | $447M | $-7M | $-6M | $-179M | $-4M | $-3M | $-3M | |
| Liabilities + Equity | $377M | $418M | $448M | $485M | $197M | $196M | $164M | $192M | $190M | $188M | |
| Shares Outstanding | 80,115,002 | 80,088,931 | 79,991,768 | 79,196,710 | · | · | 28,415 | · | · | · |
Cashflow 8
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $7M | $4M | $3M | $3M | $36.0K | $627.0K | $4M | $77.4K | $77.4K | $39.4K | |
| Operating Cash Flow | $-44M | $-36M | $-42M | $-71M | $-298.9K | $-20M | $-15M | $-39M | $-29.1K | $-618.0K | |
| CapEx | $47.0K | $24.0K | $73.0K | $140.0K | $231.0K | $162.0K | $10.0K | · | · | · | |
| Investing Cash Flow | $46M | $-285M | $8M | $41M | $10M | $15M | $26M | $38M | $0 | $-184M | |
| Stock Issued | $0 | $112M | $-9M | · | · | · | · | · | · | · | |
| Net Stock Activity | · | $112M | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $37.0K | $295.0K | $-586.0K | $365M | $19M | $-404.0K | $52.0K | $20M | $0 | $186M | |
| Free Cash Flow | · | $-36M | · | · | · | · | · | · | · | · |
Rentabilität 2
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -19.7% | -13.7% | · | -13.2% | 0.47% | -0.25% | · | 2.4% | 2.3% | 1.2% | |
| ROE | -35.8% | -23.0% | · | -20.2% | -17.2% | 10.4% | · | -132.7% | -131.2% | -68.3% |
Liquidität & Solvenz 3
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.7 | 6.2 | · | 13.3 | 0.3 | 0.7 | · | 16.1 | 26.2 | 90.4 | |
| Quick Ratio | 4.4 | 5.8 | · | 13.1 | 0.3 | 0.5 | · | 14.1 | 22.9 | 79.0 | |
| Debt / Equity | · | 0.0 | · | 0.0 | · | · | · | · | · | · |
Bewertung (TTM) 11
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-172M | $-137M | · | $-113M | $-90M | $-77M | · | · | · | · | |
| Market Cap | $610M | $717M | · | $917M | · | · | · | · | · | · | |
| Enterprise Value | · | $465M | · | $450M | · | · | · | · | · | · | |
| P/E | -0.0 | · | · | · | · | · | · | · | · | · | |
| P/B | 1.9 | 1.9 | · | 2.1 | · | · | · | · | · | · | |
| P / Tangible Book | 1.9 | 1.9 | · | 2.1 | · | · | · | · | · | · | |
| P / Cash Flow | · | -20.0 | · | · | · | · | · | · | · | · | |
| P / FCF | · | -19.9 | · | · | · | · | · | · | · | · | |
| EV / EBITDA | · | -10.1 | · | -9.1 | · | · | · | · | · | · | |
| EV / FCF | · | -12.9 | · | · | · | · | · | · | · | · | |
| Earnings Yield | -23606.3% | · | · | · | · | · | · | · | · | · |
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
Gewinn- und Verlustrechnung
| 2025-12-31 | 2024-12-31 | 2023-12-31 | |
|---|---|---|---|
| Nettoergebnis | $-134M | $-74M | $-41.7K |
| Verwässerte EPS | $-4.30 | $-5756.41 | — |
Bilanz
| 2025-12-31 | 2024-12-31 | 2023-12-31 | |
|---|---|---|---|
| Fremdkapital / Eigenkapital | 0.0 | — | — |
| Liquiditätsgrad | 12.3 | 10.4 | — |
| Quick Ratio | 12.1 | 9.1 | — |
Cashflow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | |
|---|---|---|---|
| Freier Cashflow | $-114M | — | — |
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
📊
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das ➕ neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Institutionelle Eigentümer (13F) 65 Einreicher · $429.4M gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 20 (+3 vs. Vorquartal) | 17 (+10 vs. Vorquartal) | 16 (-3 vs. Vorquartal) | 14 (+3 vs. Vorquartal) | +2.4M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| Cormorant Asset Management, LP | $136.234.886 | 17.878.594 | 31,73% | Aktien |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $37.227.099 | 4.885.446 | 8,67% | Aktien |
| Omega Fund Management, LLC | $25.067.217 | 3.289.661 | 5,84% | Aktien |
| Alphabet Inc. | $21.512.220 | 2.823.126 | 5,01% | Aktien |
| EcoR1 Capital, LLC | $21.512.220 | 2.823.126 | 5,01% | Aktien |
| WELLINGTON MANAGEMENT GROUP LLP | $21.254.481 | 2.789.302 | 4,95% | Aktien |
| ENAVATE SCIENCES GP, LLC | $20.017.329 | 2.626.946 | 4,66% | Aktien |
| CITADEL ADVISORS LLC | $19.269.166 | 2.528.762 | 4,49% | Aktien |
| NOVO HOLDINGS A/S | $17.145.000 | 2.250.000 | 3,99% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $15.283.045 | 2.005.649 | 3,56% | Aktien |
| Laurion Capital Management LP | $15.260.582 | 2.002.701 | 3,55% | Aktien |
| ARMISTICE CAPITAL, LLC | $13.441.680 | 1.764.000 | 3,13% | Aktien |
| STATE STREET CORP | $7.898.656 | 1.036.569 | 1,84% | Aktien |
| Aisling Capital Management LP | $7.757.297 | 1.018.018 | 1,81% | Aktien |
| Opaleye Management Inc. | $5.334.000 | 700.000 | 1,24% | Aktien |
| Granahan Investment Management, LLC | $4.255.968 | 558.526 | 0,99% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $3.918.497 | 513.932 | 0,91% | Aktien |
| SPHERA FUNDS MANAGEMENT LTD. | $3.512.706 | 460.985 | 0,82% | Aktien |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $3.048.000 | 400.000 | 0,71% | Aktien |
| ROYCE & ASSOCIATES LP | $2.933.250 | 384.941 | 0,68% | Aktien |
| Catalio Capital Management, LP | $2.426.261 | 318.407 | 0,57% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $2.221.398 | 291.522 | 0,52% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $2.183.267 | 286.518 | 0,51% | Aktien |
| Casdin Capital, LLC | $2.151.217 | 282.312 | 0,50% | Aktien |
| Ensign Peak Advisors, Inc | $2.084.299 | 273.530 | 0,49% | Aktien |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $1.872.418 | 244.441 | 0,44% | Aktien |
| FMR LLC | $1.833.235 | 240.582 | 0,43% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $1.456.578 | 191.152 | 0,34% | Aktien |
| NORTHERN TRUST CORP | $1.230.493 | 161.482 | 0,29% | Aktien |
| Sio Capital Management, LLC | $995.385 | 130.628 | 0,23% | Aktien |
| UBS Group AG | $873.671 | 114.655 | 0,20% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $803.758 | 105.480 | 0,19% | Aktien |
| GOLDMAN SACHS GROUP INC | $777.888 | 102.085 | 0,18% | Aktien |
| MOORE CAPITAL MANAGEMENT, LP | $762.000 | 100.000 | 0,18% | Aktien |
| Brevan Howard Capital Management LP | $690.714 | 88.895 | 0,16% | Aktien |
| Palumbo Wealth Management LLC | $652.455 | 85.624 | 0,15% | Aktien |
| BlackRock, Inc. | $566.867 | 74.392 | 0,13% | Aktien |
| Jump Financial, LLC | $472.440 | 62.000 | 0,11% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $446.532 | 58.600 | 0,10% | Aktien |
| BANK OF AMERICA CORP /DE/ | $409.072 | 53.684 | 0,10% | Aktien |
| Avidity Partners Management LP | $334.160 | 43.853 | 0,08% | Aktien |
| TD Asset Management Inc | $325.603 | 42.730 | 0,08% | Aktien |
| Virtus Investment Advisers, LLC | $321.716 | 42.220 | 0,07% | Aktien |
| VANGUARD GROUP INC | $227.401 | 18.163 | 0,05% | Aktien |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $213.238 | 27.984 | 0,05% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $201.816 | 26.485 | 0,05% | Aktien |
| Rafferty Asset Management, LLC | $172.258 | 22.606 | 0,04% | Aktien |
| CITIGROUP INC | $151.425 | 19.872 | 0,04% | Aktien |
| Squarepoint Ops LLC | $149.824 | 19.662 | 0,03% | Aktien |
| Vanguard Global Advisers, LLC | $138.402 | 18.163 | 0,03% | Aktien |
| Schonfeld Strategic Advisors LLC | $87.659 | 11.504 | 0,02% | Aktien |
| PROFUND ADVISORS LLC | $83.828 | 11.001 | 0,02% | Aktien |
| AXQ CAPITAL, LP | $81.747 | 10.728 | 0,02% | Aktien |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $20.115 | 2.626 | 0,00% | Aktien |
| BARCLAYS PLC | $15.827 | 2.077 | 0,00% | Aktien |
| Tower Research Capital LLC (TRC) | $12.924 | 1.696 | 0,00% | Aktien |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | $10.287 | 1.350 | 0,00% | Aktien |
| Rockefeller Capital Management L.P. | $7.620 | 1.000 | 0,00% | Aktien |
| Integrated Wealth Concepts LLC | $3.330 | 437 | 0,00% | Aktien |
| MORGAN STANLEY | $2.286 | 300 | 0,00% | Aktien |
| WELLS FARGO & COMPANY/MN | $2.286 | 300 | 0,00% | Aktien |
| PRICE T ROWE ASSOCIATES INC /MD/ | $2.286 | 300.000 | 0,00% | Aktien |
| Quarry LP | $1.501 | 197 | 0,00% | Aktien |
| Caitong International Asset Management Co., Ltd | $282 | 37 | 0,00% | Aktien |
| Pacer Advisors, Inc. | $3 | 378 | 0,00% | Aktien |
Unternehmensinsider 17 Insider · 5 Führungskräfte · 10 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Pedro Beltran | President and CEO | 1. Juli 2026 F | 44.576 | 0 | 0 | $0 |
| Eli M. Wallace | Chief Executive Officer | 1. Januar 2026 A | — | 0 | 0 | $0 |
| Idan Elmelech | COO & Principal Financial Ofcr | 1. Juli 2026 F | 14.495 | 0 | 0 | $0 |
| Yong Ben | Chief Med & Dev Officer | 1. Juli 2026 F | 44.576 | 0 | 0 | $0 |
| Marc Cobo | Principal Accounting Officer | 1. Juli 2026 F | 5.306 | 0 | 0 | $0 |
| Chen Bihua | Direktor | 1. Juli 2026 J | 6.083.221 | 0 | 0 | $0 |
| Peter F Lebowitz | Direktor | 16. Juni 2026 A | — | 0 | 0 | $0 |
| Raymond J. Kelleher | Direktor | 16. Juni 2026 A | — | 0 | 0 | $0 |
| Praveen P. Tipirneni | Direktor | 16. Juni 2026 A | — | 0 | 0 | $0 |
| Neil Kumar | Direktor | 16. Juni 2026 A | — | 0 | 0 | $0 |
| Jake Bauer | Direktor | 16. Juni 2026 A | — | 0 | 0 | $0 |
| Frank Mccormick | Direktor | 16. Juni 2026 A | — | 0 | 0 | $0 |
| Helix Holdings II LLC | Direktor | 8. Februar 2025 J | 509.000 | 0 | 0 | $0 |
| Uneek Mehra | — | 1. April 2026 F | 22.806 | 0 | 0 | $0 |
| Albert A Holman III | — | 11. August 2025 M | 30.000 | 0 | 0 | $0 |
| Mark C. Mckenna | — | 11. August 2025 M | 30.000 | 0 | 0 | $0 |
| John P. Schmid | — | 11. August 2025 M | 30.000 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
Aktivisten & 5%+-Eigentümer 3 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Bihua Chen, Cormorant Private Healthcare Fund III, LP, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare Fund V, LP, Cormorant Private Healthcare GP V, LLC, Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Helix Holdings II LLC | 6. Juli 2026 | 22,32% | Änderung | — | SEC |
| BridgeBio Pharma LLC, BridgeBio Pharma, Inc. | 18. August 2025 | 17,50% | Erste Einreichung | Vorstandskampagne | SEC |
| Helix Holdings II LLC, Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Bihua Chen ×3 Einreichungen | 13. August 2025 | 22,60% | Änderung | Passive Anlage | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF-Besitz Gehalten von 6 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| CANC · Tema ETF Trust | 0,48% | 93.339 NS | 31. Mai 2026 | N-PORT |
| IBB · iShares Trust | 0,03% | 316.264 SH | 8. August 2026 | Täglich |
| SCHA · SCHWAB STRATEGIC TRUST | 0,01% | 227.258 NS | 31. Mai 2026 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 27.500 NS | 31. Mai 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 549.132 SH | 8. August 2026 | Täglich |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1.422.900 SH | 8. August 2026 | Täglich |